A trial of radiolabeled antibody yttrium‐90–FF‐21101 for the treatment of advanced ovarian and other cancers

⁹⁰Y-FF-21101 did not meet the predefined efficacy criteria, and adverse events were consistent with ⁹⁰Y agents. These data may assist in the development of other P-cadherin-directed therapies (ClinicalTrials.gov identifier NCT02454010).